Royce Micro-Cap Trust outperformed the Russell 2000 in 2025, led by Industrials and Materials sectors. Read the full analysis ...

Nevada DMV data shows that 61% of SNAP recipients are overweight. The restrictions on candy and sweet drinks are connected to Medicaid cuts from President Trump's "One Big Beautiful Bill." The state ...

Royce Micro-Cap Trust advanced 16.6% on a net asset value basis and 16.1% on a market price basis in 2025, outpacing its ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an ...

Novo Nordisk's reports to the FDA spiked shortly after an inspection found the Ozempic producer ignored reports of deaths and ...

Over the past two years, Eli Lilly (NYSE: LLY) has established itself as the leader in the weight loss market. That's thanks ...

Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline.

Prices at the pump jumped 72 cents compared to a month ago in the Philadelphia Metropolitan Area as Iran war enters third ...

An experimental obesity pill from Structure Therapeutics helped patients lose significant weight in a mid-stage trial, with a ...

Tennessee Vols redshirt freshman quarterback George MacIntyre's weight has easily been one of the biggest storylines of the ...

The drug’s efficacy “looks to be highly competitive” and potentially better than rival pills from Novo and Lilly, BMO Capital Markets analyst Evan Seigerman said.